Year-over-year earnings per share growth for the last twelve months: Immatics N.V. (IMTX)

immatics.com (IMTX) - corporate logo

Immatics N.V. dominates T-cell immunotherapy thanks to its proprietary XPRESIDENT system. The quarterly EPS growth rate confirms this status, while the -25.20 value reflects the metric's balance. A flawless cold chain ensures the integrity of biologics during delivery. Current progress in treating solid tumors is creating a real effect, while the market currently prices in commercialization timeline risks.

Immatics NV (IMTX) Year-over-year net earnings per share growth for the last 12 months: for the period 07/04/2022 - 11/14/2026

Comprehensive metric breakdowns and analytics for immatics.com (IMTX)

- share price and expert price forecast:
Stock Price Immatics Biotechnologies|IMTX - Analyst Median Target
- company stock exchange capitalization indicators:
Market Value Immatics N.V.|IMTX - Real Price to Acquire Entire Company
- book capitalization data:
Net Assets per Single Share Immatics|IMTX - Company Net Assets|Market Cap to Net Assets Ratio immatics.com|IMTX - Company Total Assets
- debt and liquidity details:
Debt to Equity Immatics N.V.|IMTX - Long-Term Debt to Capital Ratio|Short-Term Debt to Equity Immatics Biotechnologies|IMTX - Company Cumulative Debt|Debt to Book Value Immatics|IMTX - Long-Term Indebtedness|Company Current Liabilities Immatics|Quick Ratio immatics.com
- earnings and market multiples details:
IMTX - Final Profit|Projected Future Earnings Immatics N.V.|IMTX - Market Cap to Earnings|Future Price to Earnings Immatics N.V.|IMTX - Growth-Adjusted Payback Ratio|EV/EBITDA Multiple Immatics Biotechnologies|IMTX - Operating profit EBITDA|Earnings per share for the last twelve months Immatics|IMTX - Earnings per one share for the last 12 months|Year-over-year net earnings per share growth for the last 12 months immatics.com|IMTX - Earnings per share growth rate in current year|Earnings growth forecast for next year Immatics N.V.
- revenue and sales proceeds data:
IMTX - Company Gross Revenue|Company Projected Revenue Immatics Biotechnologies|IMTX - Market Cap to Revenue|Price-to-Projected Revenue Ratio Immatics N.V.
Comprehensive company analysis:Immatics NV, IMTX
Manufactured product of Immatics N.V.

Investors are seeking reliable markers of financial stability in the reporting of Immatics N.V. (IMTX). This metric measures the percentage change in net income per share over the last three months. Analyzing quarterly net income per share growth allows investors to filter out market manipulations and avoid overpaying. For Immatics N.V. (IMTX), this trend reflects the cost of aggressively hiring rare immunologists. The efficiency of investments in scientific staff directly determines the future capitalization of the business.

Competitors of Immatics N.V.

IBRX: Quarterly EPS earnings growth|IMCR - Year-over-year net earnings per share change for the last twelve months|Year-over-year earnings per share growth for the last twelve months januxrx.com|Year-over-year net earnings per share growth for the last 12 months arcusbio.com (RCUS)|Year-over-year earnings per share growth for the last twelve months Zymeworks Inc (ZYME)|Year-over-year net earnings per share growth for the last 12 months Tango Pharma TNGX|Iovance Biotherapeutics Inc - Year-over-year net earnings per share growth for the last 12 months|Quarterly EPS earnings growth Xencor Inc. XNCR|CMPX - Year-over-year earnings per share growth for the last twelve months|REPL (replimune.com) - Year-over-year earnings per share growth for the last 12 months|Lyell Pharma (LYEL) - Year-over-year earnings per share growth for the last twelve months|Earnings per share growth in annualized terms for the last twelve months Innate Pharma, S.A. (IPHA)|Year-over-year net earnings per share growth for the last 12 months PYXS|CGEN - Net earnings per share growth for the trailing year|Year-over-year net earnings per share growth for the last 12 months IOBT (IO Biotech Corp)|Year-over-year earnings per share growth rate for the last twelve months STRO|Quarterly EPS earnings growth INKT (MiNK Therapeutics)|Year-over-year earnings per one share growth for the last 12 months HOWL|Immix - Quarterly EPS earnings growth|Earnings per share growth in annualized terms for the last twelve months ALX Oncology Holdings Inc.|CUE: Quarterly EPS earnings growth|PDS Biotech - Year-over-year earnings per one share growth for the last 12 months|SONN (Sonnet BioTherapeutics Holdings Inc.) - Quarterly EPS earnings growth|Quarterly EPS earnings growth MAIA Biotech|Year-over-year earnings per share growth for the last twelve months Liminatus Pharma LLC (LIMN)|LVTX: Year-over-year net earnings per share trend for the last twelve months|NextCure Inc - Year-over-year net earnings per share growth for the last 12 months|Leap Therapeutics, Inc. (LPTX) - Earnings per share growth in annualized terms for the last twelve months|Intensity Therapeutics Inc - Quarterly EPS earnings growth|Year-over-year net earnings per share change for the last twelve months senseibio.com SNSE|TOVX: Quarterly EPS earnings growth|Gritstone bio Inc. - Year-over-year earnings per one share growth for the last 12 months|Year-over-year net earnings per share growth for the last 12 months KA|Year-over-year earnings per share growth for the last 12 months NEXI (NexImmune, Inc.)|Year-over-year earnings per share growth for the last twelve months Turnstone Biologics Corporation (TSBX)|Year-over-year net earnings per share growth for the last 12 months Vaccinex VCNX|Year-over-year earnings per share growth for the last twelve months harpoontx.com HARP